BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)

BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)

Rheumatoid arthritis (RA) is a frequent and disabling disease, requiring early management to achieve clinical remission. Recently, baricitinib (jak1-jak2 inhibitor) has been shown to as an efficient treatment in placebo-controlled trials, and compared to the reference treatment with TNF inhibitor (adalimumab). Its efficacy has been reported on the inflammatory parameters, but more importantly on patient-reported outcomes. Baricitinib is thought to have anti-inflammatory effects, via its inhibition of the JAK pathway. Importantly, it has also been suggested to affect mood and pain.

Hypotheses: Inhibition of JAK Kinase pathway in patients with RA will improve emotional and cognitive processing involved in mood disorders and decrease pain sensitization.

The primary objective of this study is to evaluate early emotional impact of the JAK 1/2 inhibitor Baricitinib assessed by a facial emotion recognition task. This precocious effect on emotion processing is a surrogate marker of clinical imporvement in mood.

Phase 4 study, Double-blind randomized control study with patients receiving placebo or baricitinib for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks.

Study Overview

• Status: Terminated
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: Baricitinib Oral Tablet [Olumiant]; Drug: Placebo

Detailed Description

Rheumatoid arthritis (RA) is a frequent and disabling disease, requiring early management to achieve clinical remission. Recently, baricitinib (jak1-jak2 inhibitor) has demonstrated its efficacy compared to placebo, and compared to the reference treatment with TNF inhibitor (adalimumab). Its efficacy has been reported on the inflammatory parameters but more importantly on patient reported outcomes. Inhibition of JAK pathway could have anti-inflammatory activity but also direct action on mood and pain.

Hypotheses: Inhibition of JAK Kinase pathway in patients with RA will improve emotional and cognitive processing involved in mood disorders and decrease pain sensitization.

The primary objective of this study is to evaluate early emotional impact of the JAK 1/2 inhibitor Baricitinib assessed by Harmer's cognitive and emotional battery, This emotional aspect is a surrogate marker of future mood impact.

The primary outcome is the number of accurate responses in facial emotion recognition task at day 1 using Harmer's cognitive battery (based on Harmer & Cowen evaluation protocol at day 1).

Phase 4 study,Double-blind randomized control study with patients receiving placebo or baricitinib for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. At baseline (day 0), RA activity, mood symptoms, the number of accurate responses in facial emotion recognition task (Harmer's cognitive battery), clinical pain sensitization, will be assessed.3 follow-up research visits will be conducted at day 1, 8 and 42 (final visit) at the Pitié Salpêtrière hospital.The first intake of the Investigational medicinal product (IMP) (baricitinib or placebo) is at day 1. At day 1, the number of accurate responses in facial emotion recognition task and RA activity will be evaluated (2 to 4 hours after intake of baricitinib). At day 8 and 42, RA activity and flares, mood symptoms, the number of accurate responses in facial emotion recognition task (Harmer's cognitive battery), clinical pain sensitization, will be assessed. In each group (placebo vs Baricitinib), 20 patients will underwent a non-contrast MRI at day 0 and 8 (with evaluation of mood modification using BOLD signal during the different experimental conditions of the Cyberball task with comparison to baseline condition, and pain evaluation using fMRI-based neurological pain signature provided by Wager et al.) During the follow-up until day 42, patients will conduct questionnaires (day 15 and 29) at home about RA activity, pain (Patient pain VAS, Patient global assessment of the disease, Flare RA questionnaire) and psychometric questionnaire (Hospital Anxiety and Depression Scale)

• Study Type: Interventional
• Enrollment (Actual): 5
• Phase: Phase 4

Contacts and Locations

Study Locations

• France
  • Paris, France, 75013
    • CHU Pitie Salpetriere

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients aged between 18 and 75 years
• Diagnosis of RA according to the ACR/EULAR 2010 classification criteria
• Active rheumatoid arthritis at inclusion (defined by a Disease Activity Score (DAS28) > 3.2)
• Patient eligible for baricitinib treatment in agreement with European label and French recommendations for RA treatment with dosage of 4mg (patients with 2mg dosage will not be included to ensure patient homogeneity)
• Informed and signed consent
• Affiliation to a french social security system (beneficiary or legal)
• For child-bearing aged women, efficient contraception

Exclusion Criteria:

• Patient under tutorship or guardianship, and incapable to give informed consent
• Diagnosis of a systemic autoimmune disease other than RA

• Treatment not allowed:

  • DMARDS other than Methotrexate or Leflunomide or Hydroxychloroquine or Salazopyrine.
  • Psychotropic treatments (antidepressive drugs, benzodiazepine, mood stabilizer) during the study or the month prior the study that could change the mood evaluation.
• Laboratory exclusions: o Total white blood cell count (WBC) less than 3 x 109 cells/L o Absolute lymphocyte count (ALC) less than 0.5 x 109 cells/L o Absolute neutrophil count (ANC) less than 1 x 109 cells/L o Hemoglobin less than 8.0 g/dl o eGFR < 60 mL/min/1.73 m² based on the most recent serum creatinine (Cockroft-Gault method) o ALT or AST > 5 times upper limit of normal o Any abnormality on screening laboratory tests that, in the opinion of the investigator, could represent a risk when participating in this protocol
• Any contraindications to baricitinib treatment or to Non-contrast MRI exam
• Hypersensitivity to the active substance or to any of the excipients
• History of active tuberculosis without treatment or chronic infectious diseasewith a need of regular use of antibiotic
• Active or prior bacterial or viral infection that required treatment with antibiotics within 30 days prior to screening
• History of lymphoma or leukemia or other malignancy besides non-melanoma skin cancer within 5 years
• Uncontrolled medical condition or planned major surgery during the study
• Pregnancy or breast-feeding
• Claustrophobia
• Patient unable to understand and follow recommendations or unable to perform self-evaluation
• Participation in another interventional study or being in the exclusion period at the end of a previous study.
• Patients with current suicidal intents or behaviors, Past or present depression or anxiety will be neither a criterion for inclusion nor a criterion for non-inclusion but will be collected in case report form.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Baricitinib; Patients receiving baricitinib 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8	Drug: Baricitinib Oral Tablet [Olumiant]; Baricitinib 4 mg/d oral route for 42 days; Other Names: Baricitinib
Placebo Comparator: Placebo; Patients receiving placebo 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8	Drug: Placebo; Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of accurate responses in facial emotion recognition task	Percentage of accurate responses in facial emotion recognition task using Harmer's cognitive battery (based on Harmer & Cowen evaluation protocol)	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
DIfference in disease activity	DIfference in disease activity on DAS28 (disease activity score on 28 joints) - SDAI (Simplified Disease Activity Score)	Day 0, 8 and 42
Difference in function improvement	Difference in function improvement on HAQ (health assessment questionnaire)	Day 0, 8 and 42
Difference in pain	Difference in pain using Visual Analogic Scale (VAS) for pain	Day 0, 8 and 42
Difference in patient global assessment of the disease	Difference in VAS for patient global assessment of the disease	Day 0, 8 and 42
Number of accurate responses in facial emotion recognition task	The number of accurate responses in facial emotion recognition task using Harmer's cognitive battery (based on Harmer & Cowen evaluation protocol)	Day 8
Difference in central and peripheral pain sensitization	Difference in central and peripheral pain sensitization using quantitative sensory testing	Day 0, 8 and 42
Difference in the results of psychometric questionnaire	Difference in the results of psychometric questionnaire using Hospital Anxiety and Depression Scale	Day 0, 8 and 42
Difference in blood-oxygen-level dependent (BOLD) signal activity in regions of interest (ROI) such as the subgenual anterior cingulate cortex (Sg-ACC) during a cyberball task	Main effect of group on social exclusion-related brain responses (e.g. actiavtion of the Sg_ACC ROI)	day 0 and day 8
Difference in BOLD signal activity in pain-encoding brain regions	Main effect of group in pain-related brain responses	day 0 and day 8
Differences in mood and pain assessments between patients with high or low expectations of the drug	Main effect of group on accurate responses during the facial emotion recognition task and pain assessment variables	Day 1,8 and 42
Difference in BOLD signal activity in reward-learning related brain regions	Main effect of group reward-learning related brain responses (e.g. activation of the ventral striatum or vmPFC ROIs)	day 0 and day 8

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Bruno FAUTREL, MD, PhD, Assistance Publique - Hôpitaux de Paris; Study Chair: Florian BAILLY, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Actual): June 27, 2022
• Primary Completion (Actual): February 23, 2023
• Study Completion (Actual): March 31, 2023

Study Registration Dates

• First Submitted: January 4, 2022
• First Submitted That Met QC Criteria: February 9, 2022
• First Posted (Actual): February 14, 2022

Study Record Updates

• Last Update Posted (Estimated): November 16, 2023
• Last Update Submitted That Met QC Criteria: November 14, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: MRI; Active rheumatoid arthritis; Baricitinib treatment; Mood-improving effects
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: APHP190353; 2020-005773-27 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.

Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

• IPD Sharing Time Frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
• IPD Sharing Access Criteria: Researchers who provide a methodological sound proposal.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No